Course: Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
CME Credits: 1.00
Released: 2022-01-24
Approximately 80% of all patients with multiple sclerosis (MS) treated with anti-CD20 therapy or fingolimod have weak humoral immune responses after 2 doses of messenger RNA (mRNA) COVID-19 vaccines.- The outcome and safety of a third vaccine dose in this group is largely unknown. We reported results from a study designed to assess the immunogenicity and safety of a third dose of mRNA COVID-19 vaccine in patients with MS who were treated with anti-CD20 therapy or fingolimod.
Educational Objective
To identify the key insights or developments described in this article
View Full Course